tbuckley/cabot-search huggingface dataset:
PWE-262 Patients in england with inflammatory bowel disease (IBD) who develop colorectal cancer (CRC) have shortened survival when compared with patients with sporadic CRC
Authors: A Askari, S Nachiappan, J Murphy, S Mills, A Bottle, T Athanasiou, N Arebi, S Clark, O Faiz
Journal: Gut (2015)

<h3>Introduction</h3> Ulcerative Colitis (UC) and Crohn’s Disease (CD) are both implicated as risk factors for the development of colorectal cancer (CRC). It is unclear if this patient group has a poor survival after diagnosis. The aim of this study is to determine survival in Inflammatory Bowel Disease (IBD) associated CRC compared with sporadic CRC. <h3>Method</h3> Patients with a diagnosis of both CRC and IBD were identified from a national administrative dataset (Hospital Episode Statistics – HES). Multivariable cox proportional hazards regression analyses (adjusting for gender, age, medical comorbidity, mode of admission, operation type, chemotherapy) were used to determine survival differences. <h3>Results</h3> A total of 286,591 patients underwent surgery for CRC in England, between 1997–2012: 0.5% (n = 1,546) had UC and 0.3% (n = 776) had CD. Patients with IBD were diagnosed with CRC at a significantly younger age compared with sporadic patients (UC median age 64, CD median age 63, sporadic median age 71, p &lt; 0.001). Long-term survival in patients with IBD was poor compared with sporadic CRC patients (HR 1.19, CI 1.12–1.26, p &lt; 0.001). On sub-group analysis patients with UC had a 12% reduction in their survival (HR 1.12, CI 1.04–1.20, p = 0.003), whereas those with CD had a 32% reduction (HR 1.32, CI 1.20–1.45, p= &lt;0.01). This difference in survival persisted even when adjusting for immediate post-operative mortality. <h3>Conclusion</h3> IBD associated CRC develops at a younger age than sporadic CRC with poorer long-term survival, particularly for patients with CD. The reasons for shortened survival amongst IBD patients who develop CRC are unclear. <h3>Disclosure of interest</h3> None Declared.
Tumor volume analysis in clinical oncology.
Authors: AB Gordon, J Stebbing, C Coombes
Journal: Cancer Research (2009)

Abstract Abstract #4023 Background: RECIST 'Response Evaluation Criteria in Solid Tumors' uses the longest diameter to measure Partial Response (PR), Stable Disease (SD) and Progressive Disease (PD). When the diameter of a sphere doubles the volume increases eight times (Volume = 4/3 Π r3). We have previously proposed that data be expressed as volume in cubic centimetres rather than as longest diameter in centimetres. (Poster 2021 SABCS 2007) Ref 1.&amp;#x2028; Method: To investigate this further we assessed 56 patients from a primary breast cancer therapeutic trial. We then compared traditional RECIST measurements with our Tumor Volume Analysis TVA using a new device LCD calculator, (patent applied for number GB244189), which has three separate programs. (1) calculation of the volume of a mass in one or two or three diameters or dimensions. (2) volume comparison between a first and second mass shown as a difference in cubic centimetres or percentage. (3) diameter comparison as RECIST between a first and second mass shown as a difference in centimetres or percentage.&amp;#x2028; Results: When data are expressed as volume in cubic centimetres the response levels are higher in percentage terms. A RECIST PR of 30% becomes volume PR of 66% Table 1. Table 2 demonstrates data we have obtained using a previous study Ref 2. When the diameter is converted into volume the response levels are higher, which was statistically significant (p&amp;lt; 0.05).&amp;#x2028; Tumor Volume Analysis: A one dimensional sphere of 3cm in diameter has a volume of 14.14 cubic centimetres. A bidimensional ellipse of 3cm x 2cm has a volume of 6.28 cubic centimetres. A date shaped tri-dimensional mass 3cm x 2cm x 1cm has a volume of 3.14 cubic centimetres.&amp;#x2028; Conclusions: This demonstrates the importance of providing three dimensional measurements of a tumor. This is particularly the case in serial measurements when treatment effects are being monitored.&amp;#x2028; Ref 1 SABCS Breast Cancer Volume 106 Supplement 1 December 2007 PPS1-S302 S91&amp;#x2028; Ref 2 Polychronis et al. Lancet Oncology Volume 6, June 2005 383-391.&amp;#x2028; &amp;#x2028; &amp;#x2028; &amp;#x2028; Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 4023.
ECHOCARDIOGRAPHIC PREDICTORS OF LONG TERM OUTCOMES IN PATIENTS UNDERGOING CARDIAC RESYNCHRONIZATION THERAPY: WHAT IS THE OPTIMAL METRIC?
Authors: John Rickard, Ryan Tedford, Mark Niebauer, Mohamed Bassiouny, David Spragg, Bryan Baranowski, Bruce Wilkoff, Niraj Varma
Journal: Journal of the American College of Cardiology (2015)
PTH-122 Home Parenteral Nutrition In Palliative Care: A Retrospective Study To Identify Potential Prognostic Indicators
Authors: B Drinkwater, B Clarke, S Cooper
Journal: Gut (2014)

<h3>Introduction</h3> The use of home parenteral nutrition (HPN) in the palliative setting is less common in the UK than in Europe and the USA. It remains controversial with little evidence base supporting the existing guidance. Patient selection remains challenging. We aimed to identify potential prognostic indicators in palliative care patients receiving HPN using a retrospective analysis. <h3>Methods</h3> Palliative care patients commenced on HPN were identified. Medical notes, computer records and the HPN database were accessed to identify patient demographics, primary diagnosis and aetiology of intestinal failure, blood test results potentially associated with prognosis (eGFR, albumin (not employed as a marker of malnutrition), CRP, Hb), presence of ascites prior to starting HPN, and total number of nights on HPN. By dichotomising the blood results into CKD stage 3 or worse (eGFR &lt;60), albumin ≤30, CRP &gt;50, Hb &lt;10, we were able to derive Kaplan-Meier survival plots to identify statistical significance associated with survival. <h3>Results</h3> From the HPN database of 111 patients, 20 (18%) were identified as palliative. Six were male (30%), and the median age (interquartile range (IQR)) was 56.4 (51.5–66.8) years; range 25.2–81.6. Between 2000 and 2006 four patients commenced palliative HPN, while 2007–2013 there were 16. At the time of data collection 80% (16/20) had died. The median number (IQR) of nights spent on HPN was 85 (19–352). The most common indication for HPN (aetiology of intestinal failure) was gastro-intestinal obstruction (n = 13, 65%) and short bowel syndrome following palliative surgical resection (n = 4, 20%). The median (IQR) eGFR was 90 (53.5–90), with eGFR &lt;60 n = 4, median (IQR) albumin 30 (24.5–35); low albumin ≤30, n = 10.; median Hb 10.4 (9.3–10.9);, Hb &lt;10 n = 7; median (IQR) CRP 10.5 (3.8–89.3), high CRP &gt;50 n = 4. Of the 14 available case notes reviewed, there was evidence of ascites prior to starting HPN in 35.7% (5/14). Kaplan-Meier survival plots identified a statistically significant shorter prognosis on HPN if the presenting albumin was ≤30 p = 0.016, median 66 (5–115) days, and similarly if the CRP &gt;50 p = 0.04, median (IQR) 98 (56–122). No significance was found with low Hb, CKD stage 3 or worse or presence of ascites when compared with prognosis by Kaplan-Meier survival plots. <h3>Conclusion</h3> We conclude that a low albumin (not a marker of malnutrition) and high CRP may help to predict those who are likely to survive less long on palliative HPN. When examining median days this appears most pertinent with a low albumin. There does not appear to be any significant association between ‘presence of ascites’, a low Hb or a low eGFR and survival time on HPN. While this study does not examine quality of life, the use of albumin and CRP may help direct whether HPN may be of benefit in the palliative setting. <h3>Disclosure of Interest</h3> None Declared.
Health service reaps large benefits from volunteers, survey shows
Authors: J. Wise
Journal: BMJ (2013)

Every £1 (€1.20; $1.60) invested in the training and management of volunteers in hospitals in England yields services worth £11 in return, a new report by the King’s Fund has estimated.

The report, Volunteering in acute trusts in England: understanding the scale and impact, is based on the first national survey of volunteering in hospitals.1 Researchers contacted all 166 acute trusts in England and received responses from 99, a response rate of 60%.

The survey found that on average acute trusts have 471 …
Semiquantitative Analysis and Characterization of Physiological Biodistribution of 68Ga-DOTA-TATE PET/CT
Authors: Jolanta Kunikowska, Leszek Królicki, Dariusz Pawlak, Imene Zerizer, Renata Mikołajczak
Journal: Clinical Nuclear Medicine (2012)

The aim of this study was to describe the normal physiological distribution of 68Ga-DOTA-TATE using the SUV to reflect the density of somatostatin receptors in various organ systems. Methods A total of 250 patients (90 men and 160 women) were imaged on a Biograph 64 PET/CT TruePoint (Siemens Medical Solutions) 60 to 80 minutes after injection of 120 to 200 MBq (3.2-5.4 mCi) of 68Ga-DOTA-TATE. Visual assessment was performed on all studies on the multimodality workstation, and sites of increased uptake were recorded. The SUVmax was also calculated for each organ demonstrating increased 68Ga-DOTA-TATE uptake. Results Visual assessment of the 68Ga-DOTA-TATE PET/CT studies revealed increased uptake in the pituitary, salivary, thyroid glands, liver, spleen, adrenals, kidneys and bone reflecting normal increased somatostatin receptor expression. These sites were confirmed to be disease free on clinical follow-up and on correlation with other imaging (CT/MRI/ultrasound). Using semiquantitative analysis, SUVmax values were the highest in the pituitary gland [11 (4.5)], spleen [18.9 (6.6)], adrenal [14.0 (5.6)], and kidneys [14.2 (3.6)]. In addition, increasing uptake in the uncinate process of pancreas was noted in 12% of patients with SUVmax of 9.2 (3.3). Moderate 68Ga-DOTA-TATE uptake was also present in salivary gland [3.4 (1.8)], thyroid [2.9 (1.2)], and normal liver [6.5 (2.2)]. The bones generally showed low 68Ga-DOTA-TATE uptake with an SUVmax of 1.0 (0.3). Conclusions Knowledge of the normal 68Ga-DOTA-TATE distribution is highly important for accurate interpretation of this novel imaging modality, which is increasingly being used in the imaging of neuroendocrine tumor.
FRI0407 Accumulation of metabolic risk factors raises the risk of occurrence and progression of knee osteoarthritis: The road study
Authors: N. Yoshimura, S. Muraki, H. Oka, S. Tanaka, H. Kawaguchi, K. Nakamura, T. Akune
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Osteoarthritis (OA) and metabolic syndrome (MS) share age and obesity as risk factors. Numerous investigators have associated OA with various components of MS. However, there has been few study clarifying associations between the occurrence or progression of knee OA (KOA) and accumulation of components of MS, using a prospective cohort of general inhabitants. <h3>Objectives</h3> To clarify the association between the occurrence and progression of KOA with components of MS, including overweight (OW), hypertension (HT), dyslipidemia (DL), and impaired glucose tolerance (IGT), using a large-scale population cohort entitled ROAD (Research on Osteoarthritis/osteoporosis Against Disability). <h3>Methods</h3> Among 1690 participants (596 men, 1094 women; mean age 65.2 years old, range 23–94 years) in mountain and seaside areas from the baseline ROAD study recruited in 2005-2007, 1384 individuals (81.9%; 466 men, 918 women) completed the second survey including knee radiography 3 years later. KOA was defined as Kellgren-Lawrence (KL) grade ≥2 using paired X-ray films. Based on changes in KL grades between the baseline and second survey, cumulative incidence and progression of KOA were determined. OW, HT, DL, and IGT at baseline were assessed using standard criteria. <h3>Results</h3> The cumulative incidence of KOA among the 1384 completers over 3 years for the age groups ≤39, 40–49, 50–59, 60–69, 70–79, and ≥80 years was 0.0%, 0.8%, 6.9%, 13.2%, 17.6%, and 25.0%, respectively. Progression in the KL grades for either knee over 3 years was observed in 5.1%, 5.2%, 15.1%, 26.5%, 32.3%, and 49.4% of the participants in these age groups, respectively. Logistic regression analyses after adjusting for age, gender, regional differences, smoking, alcohol consumption, regular exercise, and past history of knee injuries revealed that the odds ratio (OR) for the occurrence of KOA significantly increased according to the number of MS components present (vs. no component; 1 component: OR 2.20; 2 components: OR 2.84; 3 or more components: OR 9.95). Similarly, the logistic regression analysis adjusted for the above variables showed that the OR for progression of KOA in either knee also significantly increased according to the number of MS components present (vs. no component; 1 component: OR 1.38; 2 components: OR 2.31; 3 or more components: OR 2.79). <h3>Conclusions</h3> Accumulation of MS components is significantly related to both occurrence and progression of KOA. MS prevention may be useful in reducing future KOA risk. <h3>Disclosure of Interest</h3> None Declared
CLINICAL APPLICATIONS OF ORTHOPEDIC SPECT IMAGING
Authors: Stephen R. Bunker, Hirsch Handmaker, William P. Schmidt, Carol J. Lewis, Donald M. Torre, Judith A. Endres
Journal: Clinical Nuclear Medicine (1986)

Bunker, Stephen R.; Handmaker, Hirsch; Schmidt, William P.; Lewis, Carol J.; Torre, Donald M.; Endres, Judith A. Author Information
BI-09 * EphA3 RECEPTOR IS A MOLECULAR TARGET EXPRESSED IN MULTIPLE COMPARTMENTS OF GBM
Authors: S. Ferluga, D. Gibo, W. Debinski
Journal: Neuro-Oncology (2014)

Eph receptor A3 belongs to the Eph family of receptor tyrosine kinases playing critical roles in cancer. We and others found this receptor to be over-expressed in Glioblastoma (GBM), but not in normal brain. EphA3 is a plasma membrane receptor, which is internalized upon ligand binding making it as an attractive target for specific drug delivery. EphA3 overexpression was found in tumor cells and tumor-initiating cells in GBM. However, we noted that EphA3-positive cells localize around the neovasculature, being consistent with tumor-infiltrating cells. Therefore, we decided to analyze EphA3 in relation to microglia/macrophages, as these cells highly infiltrate GBM favoring tumor progression. It has been demonstrated that glioma-infiltrating microglia acquire the M2 phenotype expressing CD163 and CD204 markers. Co-localization studies using immunofluorescence on tumor-derived primary cells showed that EphA3 co-localizes with CD163 on a sub-population of cells. The two markers also highly co-localize in snap-frozen sections of human GBM specimens, mainly in the perivascular region, as well as on cells within the bulk of the tumor and in the invasive ring, but not on the contralateral side of the diseased brain. EphA3 on snap-frozen specimens co-localized also with CD68, a more general macrophages marker, confirming the presence of EphA3 on these bone marrow-derived cells. Microglia/ macrophages have been shown also around tumor necrotic areas. We cultured GBM cells under normoxia, hypoxia and anoxia conditions and found that the levels of EphA3 receptor increased under anoxia compared to hypoxia, following the same pattern seen with CD163 and CD204. We have already generated a novel and specific cytotoxin capable of activating and internalizing the receptor and potently killing EphA3-overexpressing cells. In this study we demonstrate that by utilizing the EphA3 receptor, we will target not only tumor and tumor-initiating cells, but also infiltrating cells active in promoting glioma cell migration and growth.
GW25-e4148 Strategy of early detection and active management of supraventricular arrhythmia with remote monitoring: The randomized, multicenter SETAM trial
Authors: None Amara, None Montagnier, None Cheggour, None Boursier, None Gully, None Barnay, None Georger, None Deplagne, None Fromentin, None Mlotek, None Taieb
Journal: Journal of the American College of Cardiology (2014)
Coexistent Parathyroid Adenomas and Hurthle Cell Tumors: Failure of Full Detection by Subtraction Method
Authors: KEIR F. HALES, RONALD J. ROSENBERG, RICHARD P. SPENCER
Journal: Clinical Nuclear Medicine (1998)

Tc-99m sestamibi and I-123 sodium iodide studies were performed on two patients, one with a neck mass and another with suspected hyperparathyroidism. Subtraction images detected what proved to be Hurthle cell tumors in each case, but coexisting parathyroid adenomas, which were found at surgery, were not visualized. The findings indicate that both types of lesions can occur simultaneously, and that studies are needed to determine whether detailed assays of rate of washout could distinguish between the lesions.
Abstract 01: Development of a targeted panel for acute myeloid leukemia (AML) by using next-generation sequencing (NGS)
Authors: Anup Tilak, Ramakrishna Sompallae, Aaron Stence, Natalya Guseva, Aaron Bossler
Journal: Clinical Cancer Research (2016)

Abstract Background: AML is a clinically and genetically heterogeneous clonal disorder. Approximately 50% are characterized by recurrent clonal chromosome aberrations which have contributed to the classification of disease and are recognized as important prognostic factors. AML patients who lack these recurrent structural abnormalities have been grouped as “intermediate cytogenetic risk” and are being further subcategorized by the sequence alterations that are being identified. A more complete understanding of the genetic changes that are relevant to the pathogenesis of AML will improve the classification of risk and ultimately better selection of therapy. Our hypothesis is that mutational profiling and analysis of patient outcomes will help better define the risk subgroups of patients and predict prognosis in patients with AML. Methods: Archived DNA from 37 patients with various AML diagnoses were obtained with IRB approval (IRB#201502763). A panel of 30 commonly mutated genes in AML were designed using the Ion Ampliseq Designer (Ion Torrent) and targeted for “hotspot” or complete coding sequence (CDS). Genomic libraries were prepared using Ion AmpliSeq™2.0 (ThermoFisher) technology. Library clonal amplification was performed by emulsion PCR using Ion PGM™ Template OT2 Reagents Kit200. Simultaneous sequencing of clonally amplified DNA targets was performed by Ion-Torrent Personalized Genome Machine (IT-PGM) using 318v2 chip. Genomic variants were identified by variant caller3.4 and further filtered and analysed through a custom-made clinically validated pipeline. Novel mutations were confirmed by either single nucleotide primer extension or Sanger sequencing. Results: The assay successfully identified previously identified point mutations in FLT-3 and CEBPA genes. Additional variants were identified in 81% (30/37) of specimens; no mutations were found in 19% (7/37) specimens. The genes most frequently mutated were DNMT3A (23%), TET2 (17%), IDH2 (14%) and TP53 (14%). U2AF1 (11%) and RUNX1 (8%) were exclusively mutated in specimens with non-recurrent cytogenetic abnormalities. The identified variants will be used to risk stratify patients based on clinical outcome. Conclusion: This targeted multi-gene panel successfully identified several variants along with previously known mutations in archived specimens. Citation Format: Anup Tilak, Ramakrishna Sompallae, Aaron Stence, Natalya Guseva, Aaron Bossler. Development of a targeted panel for acute myeloid leukemia (AML) by using next-generation sequencing (NGS). [abstract]. In: Proceedings of the AACR Precision Medicine Series: Integrating Clinical Genomics and Cancer Therapy; Jun 13-16, 2015; Salt Lake City, UT. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(1_Suppl):Abstract nr 01.
P2-09-14: Evaluation of Angiogenesis Using Synchrotron Radiation in Xenograft Mouse Models of Breast Cancer.
Authors: S-M Gu, X Zhang, R-M Li, W Jin, Z-Z Shen, Z-M Shao, X-M Xu, J Wu
Journal: Cancer Research (2011)

Abstract Visualization of microvasculatures is an important step in understanding the mechanism of early vessel disorders in breast cancer and developing effective therapeutic strategies. However, quantitative evaluation of breast cancer angiogenesis using immunohistochemistry has been limited in generating detailed and reproducible data. To analyze the diversification of angiogenesis in the development of tumor growth and evaluate anti-vascular effects of Avastin, a new method of microvascular imaging was introduced in this paper. We used New X-ray microangiography and third-generation synchrotron radiation-based micro-computed tomography (SR micro-CT) to investigate the structures and density of microvessels at each stage of xenograft mouse models that were created by inoculation with MDA-MB-231HM cells (one breast cancer cell line with high metastasis potential). Barium Sulfate Nanoparticles, was used as a blood vessels contrast agent through left cardiac ventricle. Three dimensional structures of microvessels were displayed with a high spatial image resolution at around 20–30 μm. The density of microvessles was significantly reduced from the third week in mouse xenograft models. This observation with SR micro-CT was consistent with the results analyzed by immunohistochemical techniques. In addition, human breast cancer-bearing mice were treated site-specifically with humanized monoclonal antibody (Avastin) that targets all isoforms of VEGF-A. Tumor volume and the density of angiogenesis were significantly reduced in xenograft mouse models of breast cancer treated with avastin when compared with untreated mice as assessed by SR micro-CT. Specifically, the density of smaller vessels (di&amp;lt;50μm) was decreased significantly while the density of larger vessels was little changed in the Avastin-treated mice. Therefore, synchrotron radiation technique is a novel method for investigating breast cancer angiogenesis, and this might be considered as an additional complementary tool for more precise quantification of angiogenesis. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P2-09-14.